Bernard A. Fox Phd Email and Phone Number
Dr. Fox is an internationally recognized leader in immuno-oncology and co-founder and CEO of UbiVac who has spent more than 30 years studying how to use a patient’s immune system to fight cancer. Dr. Fox has participated in and led both preclinical and clinical studies of cancer immunotherapy. His group, in collaboration with colleagues at Shimadzu, recently identified some of cancer's "Dark Matter". This Dark Matter is a collection of non-canonical peptides presented by HLA of cancer cells. Some of these non-canonical proteins are not expressed in the thymus and have been characterized, by Drs. Cieri and Wu, as alternative cancer neoantigens, with potential for universal cancer vaccines (PMID: 33852826). Importantly, as these alternative neoantigens are short lived proteins, UbiVac's DPV-001 vaccine is enriched for these non-canonical proteins. Thus, UbiVac is poised to identify novel antigens and TCRs from patients enrolled on these trials. Dr. Fox is utilizing the disruptive innovation of UbiVac’s vaccine technology to advance treatments for patients with many types of cancer. He is also driving UbiVac’s efforts to develop vaccines that prevent cancer. He also holds the Harder Family Chair for Cancer Research, at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center and is on faculty at OHSU. His background in translational cancer immunotherapy developed from his tenure as a fellow in Dr. Steven Rosenberg’s lab at the National Cancer Institute.Dr. Fox is the current Chair of the World Immunotherapy Council, a consortium of 22 national and international cancer immunotherapy organizations and a past President of the Society for Immunotherapy of Cancer. He has published more than 170 manuscripts and book chapters, served on review committees for the NIH, FDA, philanthropic and governmental organizations in the USA, Europe and Asia, and serves on editorial boards of several scientific journals. Dr. Fox served on the board of directors of NeoPharm from 2004 to 2010, and is currently on the board of directors of the Oregon Bioscience Association. Dr. Fox lectures widely and serves on advisory boards for a number of biotechnology and pharmaceutical companies. In 2015, Dr. Fox received the Visionary/Legacy Award from the Society for Immunotherapy of Cancer (SITC). In 2020 Dr. Fox received a SITC Team Science Award and the Melanoma Foundation Onlus Bridge Award, for outstanding and lifelong contributions to melanoma research. In 2022 he received SITC’s Tara Withington Public Service Award.
-
Co-Founder / President / CeoUbivac 2005 - PresentPortland, UsUbiVac is a clinical stage immuno-oncology and cancer target discovery company engaged in the research, development and testing of therapeutic immunotherapy strategies to combat cancer. UbiVac currently has two platforms under development: 1) DPV (Dribbles Platform Vaccine) - DC-targeted microvesicles containing cancer’s dark matter /alternative cancer neoantigens + more than 300 shared cancer antigens, including "NCI-prioritized" cancer antigens, five TLR/NOD agonists and 15 DAMPs/molecular chaperones, 2) Ubiquitin Platform Vaccine (UPV). UbiVac's lead product, DPV-001, has completed an NCI-funded, randomized multi-center phase I/II clinical trial (NCT01909752) for adjuvant treatment of patients with definitively treated non-small cell lung cancer (NSCLC). Results showed induction of anti-cancer immunity in all patients and were reported in abstract format at the 2017 ASCO and SITC meetings. UbiVac also sponsored a pilot study of DPV-001 in men with advanced prostate cancer (NCT02234921). A clinical trial of DPV-001 + anti-PD-1 +/-anti-OX40 for patients with advanced triple negative breast cancer, based on strong preclinical studies (Scientific Reports | 6:37558), opened but was impacted by COVID and BMS decision to stop development of anti-OX40. In collaboration with Incyte, currently enrolling patients with advanced/metastatic head and neck cancer (HNSCC) on a trial of combination immunotherapy including DPV-001 + anti-PD-1. Analysis of the first 18 patients presented at AACR reported more than a tripling of the objective response rate in PD-1 naive patients (56% vs the 16% on label) and a 33% response rate in PD-1 experienced/refractory patients. Founded in Portland, OR in 2005 as a spin-out of the Robert W. Franz Cancer Center within the Earle A. Chiles Research Institute, at Providence Portland Medical Center, UbiVac continues to build upon the groundbreaking research being developed in the region.www.UbiVac.com
-
Harder Family Endowed Chair For Cancer Research, Member And Chief, Molecular And Tumor ImmunologyEarle A. Chiles Research Institute 1994 - PresentPortland, Or, UsDr. Fox's goals are to: 1) Develop effective immunotherapies that eliminate tumors in mice, 2) Translate these into patients with cancer, 3) Train next generation of translational investigators.The preclinical group (Dr. Shawn Jensen, David Messenheimer, Tyler Hulett and Zip Feng) use animal models to develop new strategies to augment therapeutic immunotherapy and also defines the mechanisms of T cell-mediated tumor elimination and tumor escape. The translational group (Dr. Sachin Puri, Dr. Christopher Paustian, Tyler Hulett and Zip Feng) transfer these developments into clinical trials, monitor patient’s anti-tumor immune response and develops hypotheses that are returned to the preclinical group for testing in animal models.Current efforts are directed at understanding and characterizing the cellular and humoral anti-tumor immune response. Our group has collaborations with Hong-Ming Hu's lab (EACRI) that are exploring how using autophagasomes can improve cross-presentation of tumor antigens and augment antitumor immunity. We also have a collaboration with Ann Hill’s lab that exploits their observations that vaccination with CMV vectors results in a high percentage of T cells recognizing the CMV vector. By placing tumor/tumor-associated antigens in CMV vectors we are evaluating if this strategy has therapeutic potential. Collaborations with Dominik Ruttinger, Hauke Winter and Natasja van den Engle at the LMU, Munich, Germany are translating discoveries in preclinical models into patients with non small cell lung cancer (NSCLC) and gastric cancer. Collaborations with the FDA are using micro arrays to characterize genes that are overexpressed in circulating tumor cells (CTC) with hopes of using this information to develop the next generation immunotherapies and aid in immunological monitoring and biomarker development.http://oregon.providence.org/our-services/r/robert-w-franz-cancer-research-center/ -
Adjunct Professor, Dept Molecular Microbiology And Immunology, And Member, Knight Cancer InstituteOhsu 1994 - PresentPortland, Oregon, UsDr. Fox is a member of the OHSU graduate faculty with an appointment in the Molecular Microbiology and Immunology Department. He has been a member of the OHSU Cancer Center since 1994, now the Knight Cancer Institute. Dr. Fox trains PhD and MD, PHD, candidates as well as postdoctoral fellows. -
Member Board Of DirectorsOregon Bioscience Association Feb 2014 - PresentPortland, Oregon, UsThe Oregon Bioscience Association provides a unified voice for the Oregon bioscience community by:• Representing the bioscience research-to-commercialization process• Accelerating the growth of the biosciences industry in all parts of Oregon• Enhancing the state's bioscience business and research climate• Helping attract and retain bioscience talent and companies.• Vigorously working to improve the quality of the bioscience workforce• Partnering with government at all levels to achieve its goals -
ChairWorld Immunotherapy Council Feb 2012 - PresentIn November, 2017, the World Immunotherapy Council will have an International meeting of their member societies prior to the annual meeting of the Society for Immunotherapy of Cancer (SITC).
-
AmbassadorSociety For Immunotherapy Of Cancer (Sitc) Dec 2012 - PresentMilwaukee, Wisconsin, Us -
Visiting ProfessorSun Yat-Sen Memorial Hospital, At Sun Yat-Sen University Nov 2023 - Present
-
Wine AmbassadorAdelsheim Vineyard Mar 2019 - PresentNewberg, Or, UsPromote Oregon wines at International cancer immunotherapy conferences -
Visiting ProfessorNational Taiwan University College Of Medicine, Graduate Institute Of Oncology 2018 - Present
-
Special Government EmployeeFda Mar 2020 - Mar 2024Silver Spring, Md, UsMember, US FDA Advisory Committee - CBER: Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) -
President / Immediate Past PresidentSociety For Immunotherapy Of Cancer (Sitc) 2008 - 2012Milwaukee, Wisconsin, UsThe Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals. Recent advances in immunology and biology have opened up new horizons in the field of cancer therapy, with an upsurge in the integration of new biologic agents into clinical practice.With several high-caliber scientific meetings with a focus on clinical and translational aspects of biologic approaches to cancer treatment and numerous networking opportunities unique to this organization, the Society for Immunotherapy of Cancer (SITC) has developed into the premier destination for interaction and innovation in the cancer biologics community.The goals of SITC are directed towards the rapid dissemination of information in these areas to expedite the safe transfer of both basic and applied research to the clinical setting.Core PurposeTo improve cancer patient outcomes by advancing the science, development and application of biological therapy/immunotherapy.Core ValuesInteraction/Integration - exchange of information and education among basic and translational researchers, clinicians, and young investigators; societies and groups sharing the vision and core values of SITCInnovation - challenge the thinking and seek the best research in the development of biological therapy/immunotherapyTranslation - promote the application and understanding of biological therapy/immunotherapyLeadership - define what is new and important and effectively communicate it to all relevant stakeholders
-
Vice President, International Society For Biological Therapy Of Cancer (Isbtc, Now Sitc)Society For Immunotherapy Of Cancer (Sitc) 2006 - 2008The Society for Immunotherapy of Cancer (SITC), formerly the International Society for Biological Therapy of Cancer (iSBTc).The goals of SITC are directed towards the rapid dissemination of information in these areas to expedite the safe transfer of both basic and applied research to the clinical setting.
-
Guest ProfessorXi’An Jiaotung University 1999 - 2008
-
Guest ProfessorLudwig-Maximilians-Universität München 2001 - 2002München, Bavaria, De -
Faculty, Surgical Oncology, Department Of SurgeryUniversity Of Michigan Medical School 1990 - 1994Ann Arbor, Mi, UsPart of team, led by Drs. Alfred Chang and Suyu Shu, that pioneered autologous tumor vaccination to generate T cells for adoptive immunotherapy of cancer (PMID: 9053507). Worked with Drs. Gary J. Nabel and Alfred Chang on the first in vivo gene therapy. This trial used lipofection to deliver plasmid DNA into cancer lesions. Studies demonstrated expression of transferred gene and effect of treatment (PMID: 8248244, PMID: 8155772, PMID: 7728301) -
Senior Staff FellowNational Cancer Institute 1987 - 1990Bethesda, Md, Us -
Staff FellowNational Cancer Institute 1985 - 1987Bethesda, Md, Us
Bernard A. Fox Phd Education Details
-
National Cancer Institute, NihCancer Immunotherapy -
Wayne State UniversityRegulatory Cell Biology And Biophysics
-
University Of Detroit MercyImmunology
-
University Of Detroit MercyWith A Minor In The History Of Renaissance And The Reformation
-
Divine Child High School
-
Sacred Heart Major Seminary
Frequently Asked Questions about Bernard A. Fox Phd
What company does Bernard A. Fox Phd work for?
Bernard A. Fox Phd works for Ubivac
What is Bernard A. Fox Phd's role at the current company?
Bernard A. Fox Phd's current role is Translational Cancer Immunotherapist, Biotech Entrepreneur & Academic.
What schools did Bernard A. Fox Phd attend?
Bernard A. Fox Phd attended National Cancer Institute, Nih, Wayne State University, University Of Detroit Mercy, University Of Detroit Mercy, Divine Child High School, Sacred Heart Major Seminary.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial